The antidopaminergic action of S-20098 is mediated by benzodiazepine/GABA(A) receptors in the striatum

Brain Research
C C Tenn, L P Niles

Abstract

The naphthalenic compound S-20098, which is a melatonergic agonist, inhibits [3H]diazepam binding in striatal membranes. S-20098 also inhibits apomorphine-induced turning in 6-hydroxydopamine lesioned rats. This antidopaminergic effect is blocked by either intraperitoneal injection of the central-type benzodiazepine (BZ) antagonist, flumazenil, or intrastriatal injection of the GABA(A) antagonist, bicuculline. These findings indicate that S-20098 can activate central-type BZ receptors, and its antidopaminergic action, like that of melatonin, involves a GABAergic mechanism in the striatum.

Citations

Oct 31, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Thomas C BaghaiHans-Jürgen Möller
Jun 27, 2013·Cellular and Molecular Neurobiology·Carlos Clayton Torres AguiarSilvânia Maria Mendes Vasconcelos
Sep 27, 2005·Experimental Gerontology·S R Pandi-PerumalD P Cardinali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.